Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short

Key TakeawaysAcadia Pharmaceuticals' drug missed endpoints for treating schizophrenia patients, news that sent Acadia shares sharply lower.The drug maker was looking at the potential use of its current Parkinson's psychosis medicine, Nuplazid.Acadia said it would not hold any more clinical trials for Nuplazid.Shares in Acadia were down more than 16% in late-afternoon trading. Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expa ...